NR4A1 and breast carcinoma: One possible explanation for this may be that breast cancer sub-type differentiation and the practice of hormone receptor status testing, and basing treatment on these results, are well established and routinely embedded in clinical practice (originating in the 1970s following the discovery of the estrogen receptor) [91].